# Sacubitril Valsartan in Preventing the Recurrence of Atrial Fibrillation After Ablation in Elderly Hypertensive Patients With Atrial Fibrillation

Study · id `cardio:ct-nct05528419` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05528419](<https://clinicaltrials.gov/study/NCT05528419>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05528419

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 320 participants.

## Technical summary

Registry record NCT05528419. Randomized; no masking; primary purpose treatment. Start 2023-02-06 (actual); primary completion 2026-01-22 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 320 participants (enrolled count; ClinicalTrials.gov record NCT05528419, source copy `cardio:ctgov-nct05528419-2026-02-10`, retrieved 2026-10-26)
- Started: 2023-02-06 (actual) (ClinicalTrials.gov record NCT05528419, source copy `cardio:ctgov-nct05528419-2026-02-10`, retrieved 2026-10-26)
- Primary completion: 2026-01-22 (actual) (ClinicalTrials.gov record NCT05528419, source copy `cardio:ctgov-nct05528419-2026-02-10`, retrieved 2026-10-26)
- Completion: 2026-02-01 (actual) (ClinicalTrials.gov record NCT05528419, source copy `cardio:ctgov-nct05528419-2026-02-10`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT05528419, source copy `cardio:ctgov-nct05528419-2026-02-10`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05528419-2026-02-10`, retrieved 2026-10-26)

## The registry's words

- Brief title: Sacubitril Valsartan in Preventing the Recurrence of Atrial Fibrillation After Ablation in Elderly Hypertensive Patients With Atrial Fibrillation
- Condition: Atrial Fibrillation Recurrent
- Condition: Hypertension
- Intervention (Drug): Sacubitril-valsartan
- Intervention (Drug): Valsartan
- Lead sponsor: Shanghai Jiao Tong University School of Medicine
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry intervention name matches this record: Valsartan (`cardio:valsartan`)
- Registry lists this organization as the lead sponsor: Shanghai Jiao Tong University School of Medicine (`cardio:org-shanghai-jiao-tong-university-school-of-medicine`)

## Provenance

Content hash: 79aea747b156ff9e0c993bc1556e1aab16265912eef7a86a14aa368fe6415662
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
